Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Pre-Market Trading 05-16 09:19:03 EDT

1.08

-0.01

-0.92%

High1.11	Low1.08	Vol71.65K
Open1.09	D1 Closing1.09	Amplitude2.72%
Mkt Cap40.61M	Tradable Cap17.92M	Total Shares37.61M
T/O78.05K	T/O Rate0.43%	Tradable Shares16.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":1.08,"timestamp":1715803200000,"preClose":1.09,"halted":0,"volume":71647,"delay":0,"floatShares":16590530,"shares":37606436,"eps":-1.287613,"marketStatus":"Pre-Market Trading","change":-0.01,"latestTime":"05-16 09:19:03 EDT","open":1.09,"high":1.1096,"low":1.08,"amount":78050.5007779,"amplitude":0.027156,"askPrice":1.26,"askSize":500,"bidPrice":0.84,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-1.287613,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1715866200000},"marketStatusCode":1,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":1.08,"postHourTrading":{"tag":"盘后","latestPrice":1.09,"preClose":1.08,"latestTime":"16:58 EDT","volume":1720,"amount":1872.1362,"timestamp":1715806734589},"volumeRatio":0.3800869593934296},"requestUrl":"/m/hq/s/UNCY/wiki","defaultTab":"wiki","newsList":[{"id":"2435077668","title":"Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435077668","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435077668?lang=en_us&edition=fundamental","pubTime":"2024-05-16 01:30","pubTimestamp":1715794225,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research Report) an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-perspective-therapeutics-catx-and-unicycive-therapeutics-uncy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-perspective-therapeutics-catx-and-unicycive-therapeutics-uncy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435563548","title":"Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2435563548","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2435563548?lang=en_us&edition=fundamental","pubTime":"2024-05-15 11:03","pubTimestamp":1715742180,"startTime":"0","endTime":"0","summary":"– OLC Demonstrates Bioequivalence to Lanthanum Carbonate – – Additional Poster Highlights Key Features of OLC as Perceived by Renal Dieticians – LOS ALTOS, Calif., May  15, 2024  (GLOBE NEWSWIRE) -- U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/15/2882293/0/en/Unicycive-Therapeutics-Presents-Bioequivalence-Data-on-Oxylanthanum-Carbonate-OLC-at-the-National-Kidney-Foundation-Spring-Clinical-Meeting.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435545263","title":"Unicycive Therapeutics reports Q1 GAAP EPS of -$0.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2435545263","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435545263?lang=en_us&edition=fundamental","pubTime":"2024-05-15 00:36","pubTimestamp":1715704612,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics press release  (NASDAQ:UNCY): Q1  GAAP EPS of -$0.61.\nCash Position: As of March 31, 2024, cash and cash equivalents totaled $48.9M.\nThe company believes that it has sufficient resources to fund planned operations into 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105968-unicycive-therapeutics-reports-q1-gaap-eps-of-061","is_publish_highlight":false,"gpt_icon":0},{"id":"2435548402","title":"Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435548402","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435548402?lang=en_us&edition=fundamental","pubTime":"2024-05-14 23:40","pubTimestamp":1715701206,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Unicycive Therapeutics (UNCY – Research Report) and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-unicycive-therapeutics-uncy-nurix-therapeutics-nrix?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-unicycive-therapeutics-uncy-nurix-therapeutics-nrix?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435590480","title":"Noble Financial Remains a Buy on Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435590480","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435590480?lang=en_us&edition=fundamental","pubTime":"2024-05-14 20:25","pubTimestamp":1715689535,"startTime":"0","endTime":"0","summary":"In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-remains-a-buy-on-unicycive-therapeutics-uncy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-remains-a-buy-on-unicycive-therapeutics-uncy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435945525","title":"Piper Sandler Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435945525","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435945525?lang=en_us&edition=fundamental","pubTime":"2024-05-14 19:21","pubTimestamp":1715685701,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-unicycive-therapeutics-uncy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-unicycive-therapeutics-uncy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435307204","title":"Unicycive Therapeutics Q1 2024 GAAP EPS $(0.61) Misses $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2435307204","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2435307204?lang=en_us&edition=fundamental","pubTime":"2024-05-14 04:38","pubTimestamp":1715632701,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.15) by 306.67 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38801775/unicycive-therapeutics-q1-2024-gaap-eps-0-61-misses-0-15-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2435302030","title":"Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435302030","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2435302030?lang=en_us&edition=fundamental","pubTime":"2024-05-14 04:16","pubTimestamp":1715631360,"startTime":"0","endTime":"0","summary":"– On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate  in Q2 2024 –。– Multiple Presentations on OLC and UNI-494 at Prominent, Upcoming Medical Meetings –。Multiple presentations related to OLC and UNI-494 will be presented at the National Kidney Foundation  Spring Clinical Meeting  and the 61st European Renal Association  Congress . Among these presentations, a poster titled “Renal Dietitians Perceive Phosphate Binder and Low Phosphorus Diet Non-Compliance as Top Reasons for Above Target Serum Phosphorus Concentrations”, by lead author Kathleen M. Hill Gallant from the University of Minnesota-Twin Cities was among the top-rated submissions to the NKF Spring Clinical Meeting. The poster reports on the findings from a survey of 100 renal dietitians on fac","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GldtEVoS99x87WCmslYrsg--~B/aD00ODQ7dz04MTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3692a6cc1430d6e658d9a99c4222d3c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GldtEVoS99x87WCmslYrsg--~B/aD00ODQ7dz04MTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3692a6cc1430d6e658d9a99c4222d3c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unicycive-announces-first-quarter-2024-201600365.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432523524","title":"3 Top Penny Stocks to Buy for Explosive Returns: April Edition","url":"https://stock-news.laohu8.com/highlight/detail?id=2432523524","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2432523524?lang=en_us&edition=fundamental","pubTime":"2024-05-01 19:00","pubTimestamp":1714561200,"startTime":"0","endTime":"0","summary":"Plan to add these top penny stocks to your portfolio now.SoundHound AI : It’s working with Nvidia, which just invested $3.7 million in the stock.American Lithium : With lithium prices showing signs of finally bottoming out, keep an eye on American Lithium.Unicycive Therapeutics : Analysts at Piper Jaffray rate UNCY as a buy, with a $9 price target.As theU.S. Securities and Exchange Commission  states, “Penny stocks may trade infrequently — which means that it may be difficult to sell penny stock shares once you have them. Because it may also be difficult to find quotations for penny stocks, they may be impossible to accurately price. Investors in penny stock[s] should be prepared for the possibility that they may lose their whole investment.”Moving forward, he sees lithium prices averaging about $14,000 this year. For 2025, he sees lithium prices of about $16","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/3-top-penny-stocks-to-buy-for-explosive-returns-april-edition/","is_publish_highlight":false,"gpt_icon":0},{"id":"2431848802","title":"These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2431848802","media":"TipRanks","top":-1,"share":"https://ttm.financial/m/news/2431848802?lang=en_us&edition=fundamental","pubTime":"2024-04-30 01:37","pubTimestamp":1714412220,"startTime":"0","endTime":"0","summary":"‘Audentes Fortuna iuvat,’ wrote Virgil in his classic epic, the Aeneid. The saying, translated as ‘Fortune favors the bold,’ means that Fortuna, the Goddess of luck, is more likely to help those who take risks or action.The stock market gives us one of the clearest examples of this principle with penny stocks. These low-cost shares, listed at $5 or less, present a rock-bottom entry point, making them true gold for the risk-tolerant investor.The appeal is clear. For the same price as one share of a more well-known company, investors can snap up hundreds of shares of a penny stock. What’s more, the fact that even minor share price appreciation can translate to hefty percentage gains is too enticing for some investors to ignore.The company has completed enrollment in a pivotal late-stage clinical trial, conducted in an open-label, single-arm, multicenter, multidose format. Anticipated in late 2Q24, the release of topline data from this trial marks a crucial step forward in Unicycive’s jou","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2Y8MgrYfsk8OnhRrCsZbcg--~B/aD00NjM7dz04NTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/8d36b5c89a47b22b8df8897b34b08898","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2Y8MgrYfsk8OnhRrCsZbcg--~B/aD00NjM7dz04NTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/8d36b5c89a47b22b8df8897b34b08898"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/2-strong-buy-penny-stocks-173700369.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/2-strong-buy-penny-stocks-173700369.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426458294","title":"Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2426458294","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426458294?lang=en_us&edition=fundamental","pubTime":"2024-04-12 03:05","pubTimestamp":1712862321,"startTime":"0","endTime":"0","summary":"Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Unicycive Therapeutics (UNCY – Research Report). The associated price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-unicycive-therapeutics-on-strong-trial-progress-and-financial-positioning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-unicycive-therapeutics-on-strong-trial-progress-and-financial-positioning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426946925","title":"Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2426946925","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2426946925?lang=en_us&edition=fundamental","pubTime":"2024-04-10 19:03","pubTimestamp":1712746980,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., April 10, 2024  -- Unicycive Therapeutics, Inc. , a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company update at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on Thursday April 18, 2024 at 11:00 a.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate , is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23048906","is_publish_highlight":false,"gpt_icon":0},{"id":"2424903363","title":"Unicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKD","url":"https://stock-news.laohu8.com/highlight/detail?id=2424903363","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2424903363?lang=en_us&edition=fundamental","pubTime":"2024-04-04 17:05","pubTimestamp":1712221541,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi. Yasmeen Rahimi’s rating is based o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/unicycive-therapeutics-a-strong-buy-on-olcs-potential-to-revolutionize-hyperphosphatemia-treatment-in-ckd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/unicycive-therapeutics-a-strong-buy-on-olcs-potential-to-revolutionize-hyperphosphatemia-treatment-in-ckd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2424923257","title":"CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2424923257","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2424923257?lang=en_us&edition=fundamental","pubTime":"2024-04-01 19:04","pubTimestamp":1711969449,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.17) by 29.41 percent. This is a 56.86 percent increase over losses of $(0.51) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/04/38018922/correction-on-friday-unicycive-therapeutics-reported-q4-eps-of-0-22-which-missed-0-17-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2424799400","title":"Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing","url":"https://stock-news.laohu8.com/highlight/detail?id=2424799400","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2424799400?lang=en_us&edition=fundamental","pubTime":"2024-04-01 18:25","pubTimestamp":1711967151,"startTime":"0","endTime":"0","summary":"In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-unicycive-therapeutics-amidst-positive-milestones-and-solid-financial-footing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-unicycive-therapeutics-amidst-positive-milestones-and-solid-financial-footing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2423121161","title":"Unicycive Therapeutics GAAP EPS of -$1.28, revenue of $0.7M","url":"https://stock-news.laohu8.com/highlight/detail?id=2423121161","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2423121161?lang=en_us&edition=fundamental","pubTime":"2024-03-29 05:03","pubTimestamp":1711659780,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics press release  : FY  GAAP EPS of -$1.28.More on Unicycive Therapeutics  Unicycive rises 4% on $50M private placement Seeking Alpha’s Quant Rating on Unicycive Therapeutics Historical earnings data for Unicycive Therapeutics Financial information for Unicycive Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4085214-unicycive-therapeutics-gaap-eps-of-1_28-revenue-of-0_7m","is_publish_highlight":false,"gpt_icon":0},{"id":"2423712530","title":"Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2423712530","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2423712530?lang=en_us&edition=fundamental","pubTime":"2024-03-28 20:15","pubTimestamp":1711628100,"startTime":"0","endTime":"0","summary":"– Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/28/2854488/0/en/Unicycive-Therapeutics-Announces-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422599999","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2422599999","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2422599999?lang=en_us&edition=fundamental","pubTime":"2024-03-25 18:00","pubTimestamp":1711360800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.PaySign Inc. Class B                            4Q       .02   4:05 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2422590370","title":"Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2422590370","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2422590370?lang=en_us&edition=fundamental","pubTime":"2024-03-25 11:03","pubTimestamp":1711335780,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., March  25, 2024  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/03/25/2851499/0/en/Unicycive-Therapeutics-to-be-Featured-in-Multiple-Presentations-at-the-Upcoming-European-Renal-Association-Congress.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419795859","title":"BRIEF-Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2419795859","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2419795859?lang=en_us&edition=fundamental","pubTime":"2024-03-15 04:42","pubTimestamp":1710448943,"startTime":"0","endTime":"0","summary":"March 14  - Unicycive Therapeutics Inc :   * UNICYCIVE THERAPEUTICS INC:  ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN ACCREDITED INVESTORS   * UNICYCIVE THERAPEUTICS: PURSUANT TO AGREEMENT CO AGREED TO ISSUE & SELL, IN  PRIVATE PLACEMENT 50,000 SHARES OF ITS SERIES B CONVERTIBLE PREFERRED STOCK   * UNICYCIVE THERAPEUTICS INC: PURCHASE PRICE OF $1,000 PER SHARE WITH AN INITIAL CONVERSION PRICE OF $1.00 PER SHARESource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":-0.0442},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.1756},{"period":"6month","weight":1.1484},{"period":"1year","weight":-0.2117},{"period":"ytd","weight":0.2447}],"compareEarnings":[{"period":"1week","weight":0.0243},{"period":"1month","weight":0.0502},{"period":"3month","weight":0.0553},{"period":"6month","weight":0.1752},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.1146}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.","exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction